Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib

Youngmok Park, Hyemin Kim, Eui Hyun Kim, Chang-Ok Suh, Soohyeon Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab therapy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.

Original languageEnglish
Pages (from-to)403-408
Number of pages6
JournalCancer Research and Treatment
Volume48
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Brain
Radiotherapy
Simple Mastectomy
Therapeutics
Adjuvant Chemotherapy
Lymph Node Excision
Blood-Brain Barrier
Doxorubicin
Cyclophosphamide
Central Nervous System
lapatinib
Combined Pituitary Hormone Deficiency
Trastuzumab
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{fe63d32f76d54e028d4ee7fc0067694f,
title = "Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib",
abstract = "Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab therapy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.",
author = "Youngmok Park and Hyemin Kim and Kim, {Eui Hyun} and Chang-Ok Suh and Soohyeon Lee",
year = "2016",
month = "1",
day = "1",
doi = "10.4143/crt.2014.165",
language = "English",
volume = "48",
pages = "403--408",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib. / Park, Youngmok; Kim, Hyemin; Kim, Eui Hyun; Suh, Chang-Ok; Lee, Soohyeon.

In: Cancer Research and Treatment, Vol. 48, No. 1, 01.01.2016, p. 403-408.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib

AU - Park, Youngmok

AU - Kim, Hyemin

AU - Kim, Eui Hyun

AU - Suh, Chang-Ok

AU - Lee, Soohyeon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab therapy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.

AB - Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab therapy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84957557957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957557957&partnerID=8YFLogxK

U2 - 10.4143/crt.2014.165

DO - 10.4143/crt.2014.165

M3 - Article

C2 - 25715765

AN - SCOPUS:84957557957

VL - 48

SP - 403

EP - 408

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -